by Nicholas C Turner, Belinda Kingston, Lucy S Kilburn,
Sarah Kernaghan, Andrew M Wardley, Iain R Macpherson, Richard D Baird, Rebecca
Roylance, Peter Stephens, Olga Oikonomidou, Jeremy P Braybrooke, Mark Tuthill,
Jacinta Abraham, Matthew C Winter, Hannah Bye, Michael Hubank, Heidrun
Gevensleben, Ros Cutts, Claire Snowdon, Daniel Rea, David Cameron, Abeer
Shaaban, Katrina Randle, Sue Martin, Katie Wilkinson, Laura Moretti, Judith M
Bliss, Alistair Ring
The Lancet
Oncology: VOLUME
21, ISSUE 10, P1296-1308, OCTOBER 01, 2020
ctDNA testing offers accurate, rapid genotyping that enables
the selection of mutation-directed therapies for patients with breast cancer,
with sufficient clinical validity for adoption into routine clinical practice.
Our results demonstrate clinically relevant activity of targeted therapies against
rare HER2 and AKT1 mutations, confirming these mutations could be targetable
for breast cancer treatment...
